Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency

Neurology

Volumn 73, Issue 8, 2009, Pages 633-637

  Porta, F ^a   Mussa, A ^a   Concolino, D ^b   Spada, M ^a   Ponzone, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; 6 PYRUVOYLTETRAHYDROPTERIN SYNTHASE; CARBIDOPA; CATECHOLAMINE DERIVATIVE; ENTACAPONE; LEVODOPA; PRAMIPEXOLE; PROLACTIN; SELEGILINE; TETRAHYDROBIOPTERIN;

6 PYRUVOYLTETRAHYDROPTERIN SYNTHASE DEFICIENCY; ADOLESCENT; ADULT; ARTICLE; BEHAVIOR DISORDER; CATECHOLAMINE BLOOD LEVEL; CHILD; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME DEFICIENCY; FEMALE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; INFANT; MALE; MOTOR DYSFUNCTION; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

EID: 69449101918     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181b38983     Document Type: Article

References (20)

1. Blau N, Thöny B, Cotton RG, Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Valle D, Sly WS, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001:1725-1776.
2. Bonafé L, Thöny B, Penzien JM, Czarnecki B, Blau N. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 2001;69:269-277. (Pubitemid 32695200)
3. Niederwieser A, Leimbacher W, Curtius HC, Ponzone A, Rey F, Leupold D. Atypical phenylketonuria with "dihydrobiopterin synthetase" deficiency: absence of phosphate-eliminating enzyme activity demonstrated in liver. Eur J Pediatr 1985;144:13-16.
4. Blau N, Thony B, Spada M, Ponzone A. Tetrahydrobiopterin and inherited hyperphenylalaninemias. Turk J Pediatr 1996;38:19-35.
5. Ponzone A, Ferraris S, Baglieri S, Spada M. Treatment of tetrahydrobiopterin deficiencies. In: Blau N, ed. PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin. Heilbronn: SPS Verlagsgesellschaft; 2006:612-637.
6. Schuler A, Blau N, Ponzone A. Monoamine oxidase inhibitors in tetrahydrobiopterin deficiency. Eur J Pediatr 1995;154:997. Letter.
7. Ponzone A, Baglieri S, Battistoni G, Martini A, Spada M. COMT inhibitors in the treatment of tetrahydrobiopterin deficiency. Pteridines 2001;12:70. Letter.
8. Ponzone A, Guardamagna O, Ferraris S, Bracco G, Cotton RG. Screening for malignant phenylketonuria. Lancet 1987;1:512-513. Letter.
9. Oppliger T, Thöny B, Kluge C, et al. Identification of mutations causing 6-pyruvoyl-tetrahydropterin synthase deficiency in four Italian families. Hum Mutat 1997;10:25-35. (Pubitemid 27298946)
10. Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarriés J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 1994;9:76-83. (Pubitemid 24022618)
11. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995;290:29-36.
12. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168. (Pubitemid 27328697)
13. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261-309. (Pubitemid 34533757)
14. Martinez S, Guilleminault C. Periodic leg movements in prepubertal children with sleep disturbance. Dev Med Child Neurol 2004;46:765-770. (Pubitemid 39468025)
15. Guilleminault C, Palombini L, Pelayo R, Chervin RD. Sleepwalking and sleep terrors in prepubertal children: what triggers them? Pediatrics 2003;111:17-25.
16. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-829. (Pubitemid 47243713)
17. Spada M, Ferraris S, Ferrero GB, et al. Monitoring treatment in tetrahydrobiopterin deficiency by serum prolactin. J Inherit Metab Dis 1996;19:231-233. (Pubitemid 26141433)
18. Jäggi L, Zurflüh MR, Schuler A, et al. Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 2008;93:295-305. (Pubitemid 351200586)
19. Biglan KM, Holloway RG. A review of pramipexole and its clinical utility in Parkinson's disease. Expert Opin Pharmacother 2002;3:197-210. (Pubitemid 34149677)
20. Bartholomé K, Byrd DJ. L-dopa and 5-hydroxytryptophan therapy in phenylketonuria with normal phenylalaninehydroxylase activity. Lancet 1975;2:1042-1043. Letter.